Promising technology out of UCSF to use droplets as containers for single-cell interaction assays Way back in 2009 I remember the first time my sales manager at RainDance Technologies presented their core technology to a sophisticated group at the US National Institutes of Health, with an introduction to microfluidics. He began by saying “Microfluidics has … Read more
There is a numbers problem, and a biomarker one as well. Annually the worldwide cancer drug market is on the order of $110 Billion, and individual immuno-oncology drugs cost the US healthcare system on the order of $100K to $150K per year. With such large financial incentives, there are currently over 900 existing clinical trials at clinicaltrials.gov … Read more
A ‘gold rush’ multi-billion dollar business, three targets, four cancer drugs, four antibody-based companion diagnostic tests, sixteen FDA approvals The human immune system is remarkable. When you think about the preponderance of death by infectious disease throughout history, the top two causes of death in 1900 was influenza and pneumonia, followed by tuberculosis, at 202 … Read more